Initial Results From Phase I/Ii Study Of Arv-766 In Mcrpc

Initial results from Phase I/II Study of ARV-766 in mCRPC

The potential role of ARV-766, an oral PROTAC AR degrader, in mCRPC

Results of Phase I Study Reach Primary End Point for mCRPC

Targeted Oncology

A phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive mCRPC

Results from a phase I study of AMG 160

European Association of Urology

PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

Prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging

Phase I/II trial of BMS-986365 in mCRPC resistant to ARPIs

PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC

GU Oncology Now

A. Edward Yen - Prostate Cancer Highlights from GU ASCO and ASCO 2024

Grand Rounds in Urology

Phase 1 Trial of ARV-110 in Patients with mCRPC

Grand Rounds in Urology

Interim results from Phase II trial of atezolizumab and SBRT in cervical cancer

First-line treatments for patients with mHSPC and mCRPC

PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC

VISION: safety analysis of 177Lu-PSMA-617 in mCRPC

Updated Phase I study results of PHE885 in patients with R/R multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

STARTAR: ADT + apalutamide + RT + docetaxel for PSA-recurrent prostate cancer following RP

VBIR vaccine shows promise in prostate cancer: Phase I trial results and immunotherapy potential

How will the results of the SPARTAN study impact US clinical practice in prostate cancer?

Prostate Cancer measured in ArcCheck of SunNuclear

Isocenter Group